Organ recovery biotech Angion Biomedica files for a $35 million IPO

By
A A A

Angion Biomedica, which develops a therapy for injured organs that triggers the body's natural regenerative process, filed on Monday with the SEC to raise up to $35 million in an initial public offering. Its lead candidate is designed to speed the recovery time for patients after a kidney transplant, but Angion believes it can be used to prevent and repair damage to other organs as well.

The Uniondale, NY-based company, which was founded in 1998 and booked $7 million in grant revenue for the fiscal year ended December 31, 2013, plans to list on the NASDAQ under the symbol ANGN. Angion Biomedica initially filed confidentially on March 4, 2014. Aegis Capital is the sole bookrunner on the deal. No pricing terms were disclosed.



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: News Headlines , IPOs

Referenced Stocks:

Renaissance Capital

Renaissance Capital

More from Renaissance Capital:

Related Videos

Stocks

Referenced

Most Active by Volume

183,639,073
  • $42.32 ▲ 3.85%
82,623,623
  • $15.99 ▼ 22.79%
39,547,942
  • $119 ▲ 1.19%
32,107,751
  • $77.62 ▲ 2.63%
29,684,848
  • $10.60 ▲ 2.02%
27,615,309
  • $24.03 ▲ 0.38%
26,917,669
  • $31.10 ▲ 2.07%
26,464,306
  • $47.75 ▲ 0.59%
As of 11/26/2014, 04:15 PM

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com